Colorectal cancer risk remains despite modern treatment for ulcerative colitis

January 09, 2020

Patients with the inflammatory bowel disease ulcerative colitis have a higher risk of dying from colorectal cancer, despite modern therapy, even though the risk has declined in recent years. This is according to a new study published in the scientific journal The Lancet by a team of Swedish and Danish researchers.

Previous research has shown that patients with ulcerative colitis have an increased risk of colorectal cancer. Screening recommendations are therefore in place for this patient group. But to what extent have new therapeutic methods helped to reduce this risk? This much-debated question has now found new answers. A large study involving 96,000 patients diagnosed with ulcerative colitis between the years 1969 and 2017 has now shown that these patients run a higher risk of developing and dying of colorectal cancer.

"The risk of colorectal cancer has dropped substantially over the past 30 years, but in spite of this patients who have had access to modern treatments for ulcerative colitis and screening for colorectal cancer still have a significantly elevated risk," says Ola Olen, senior researcher at the Department of Medicine in Solna at Karolinska Institutet in Sweden.

Seen over the entire study period (1969 - 2017) the chances of a patient with ulcerative colitis being diagnosed with colorectal cancer were 66 percent higher than the control group, with the corresponding mortality rate 59 percent higher. For the latest five-year period only, however, these figures were, respectively, 38 percent and 25 percent.

This study differs from previous ones in that it factored in both the tumour stage when the cancer risk was assessed and the mortality rates, which the researchers included to ensure that the risks were not being over-estimated. The reason for examining mortality from colorectal cancer and not only incidence for this cancer is that regular endoscopic screening might detect relatively early forms of colorectal cancer that would otherwise go undetected.

"An important result of the study is that the risks are indeed elevated but there are major differences from one patient group to another," says Olen.

At particularly high risk of developing colorectal cancer are the patients with extensive colitis, primary sclerosing cholangitis (a liver complication sometimes seen in ulcerative colitis), heredity for colorectal cancer susceptibility or childhood onset ulcerative colitis.

According to co-author and Professor Jonas F Ludvigsson, the study indicates a need to develop the care provided for these patients even further.

"Our study shows that screening and treatment of these patients can likely be further improved, since patients with ulcerative colitis are still more likely to die of colon cancer," he says.
-end-
Funding for this project was provided, in part, by the Swedish Medical Society, Mag-tarmfonden, Karolinska Institutet Foundations, the Strategic Research Area Epidemiology programme at Karolinska Institutet, the Swedish Cancer Society, the Stockholm County Council, the Swedish Research Council, the Swedish Foundation for Strategic Research, the FORTE Foundation, the Swedish Cancer Foundation and the Independent Research Fund Denmark.

Publication: "Colorectal cancer in ulcerative colitis: A Scandinavian population-based cohort study". Ola Olén, Rune Erichsen, Michael C Sachs, Lars Pedersen, Jonas Halfvarson, Johan Askling, Anders Ekbom, Henrik Toft Sørensen, Jonas F Ludvigsson, The Lancet, online January, 2020.

Karolinska Institutet

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.